查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827979

基因治療市場按載體類型、治療方法、目標基因組、遞送方法、給藥途徑、患者類型、治療領域和最終用戶分類——全球預測 2025-2032

Gene Therapy Market by Vector Type, Treatment Modality, Target Genome, Delivery Mode, Route of Administration, Patient Type, Therapeutic Area, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年基因治療市場將成長至 759.2 億美元，複合年成長率為 28.33%。

主要市場統計數據
基準年2024年 103.1億美元
預計2025年 129.1億美元
預測年份：2032年 759.2億美元
複合年成長率（%） 28.33%

基因治療從實驗突破到相關人員綜合開發和商業化的演化背景

基因治療領域已從概念驗證發展成為一個成熟的生態系統，臨床療效、監管清晰性和生產規模融合，最終形成一條商業性路徑。載體工程和基因編輯平台的持續科學突破，加上對長期安全性的深入理解，擴大了可治療疾病的範圍，並提升了投資者和付款人的興趣。因此，如今的策略重點不僅包括加速臨床轉化，還包括確保強大的供應鏈、標準化的分析方法以及永續的生產模式，以支持可重複的商業性上市。

全球監管機構日益注重協調產品特性、劑量滴定和長期追蹤的指導，影響研究設計和核准策略。同時，付款人和衛生技術評估組織正在測試針對一次性和持久治療的創新報銷機制，這促使製造商制定更嚴格的真實世界證據產生計畫。從單一專案的突破性進度到複雜的產品生命週期管理，需要涵蓋研發、監管策略、製造和商業營運的綜合能力。

在此背景下，決策者必須權衡技術選擇（例如載體系統和遞送方法）與臨床目標、患者群體和物流限制。學術界、生物技術、合約研究公司和臨床網路之間的多學科合作對於加快進度並確保安全和品質至關重要。本執行摘要的其餘部分概述了結構性轉變、政策影響、基於細分市場的洞察、區域動態以及實用建議，以幫助準備整個基因治療價值鏈的策略性投資和營運。

識別同步的技術、製造、監管和付款人轉變，重新定義基因治療的發展重點和商業性可行性

基因治療領域正被幾個並行發生、相互促進的變革性轉變所重塑。首先，平台多樣化正在加速。載體技術和基因組修飾方法正變得更加專業化，使得治療能夠根據疾病生物學和患者群體進行客製化。這種技術多樣化正在引發開發平臺的重新配置，早期專案現在強調載體最佳化、有效載荷設計和可製造性同步進行，而不是依次進行。

其次，製造和供應鏈的複雜性正在成為策略瓶頸和差異化因素。開發商正在投資模組化、靈活的製造能力，並深化與合約開發和製造機構的合作，以降低與病媒稀缺和批次差異相關的風險。除了營運重點之外，他們也越來越重視分析的穩健性和可比性研究，以確保批次一致性和法規的可接受性。

第三，付款方與醫療體系的對話正從假設性的可負擔性討論轉向探索基於結果的合約、年金模式以及對真實世界證據的承諾的具體安排。這些資金籌措機制正在影響定價策略、終點選擇和上市後證據項目。最後，監管的成熟度仍然是一個主要推動力，導致針對未滿足需求高的適應症的指導意見不斷更新，並加速了核准流程。這一轉變需要跨科學、營運和商業學科的綜合策略規劃。

檢驗2025 年美國關稅調整如何擴大供應風險、重塑籌資策略並加速基因治療的區域製造業投資

美國於2025年實施的關稅變化和貿易政策轉變，為基因治療生態系統中的機構帶來了新的成本和物流考量。隨著成本敏感型組件、試劑和專用設備跨境流通，這些政策調整提升了地理分佈的供應鏈和製造佈局的重要性。各公司正在重新調整籌資策略和庫存政策，以便在不影響臨床進度的情況下吸收或轉嫁增加的進口關稅。

管理階層的即時因應措施包括盡可能優先考慮在地採購、加速替代供應商的資格審核，以及擴大區域製造能力以降低跨境風險。成本壓力正促使一些開發商重新協商供應商契約，或與製造外包更緊密地合作，以找到互惠互利的效率。隨著時間的推移，策略資本配置正在轉向關鍵製造業務的在岸或近岸能力，尤其是載體製造和填充及表面處理工程，以保護專案免受關稅波動的影響。

在專案層面，這些貿易動態也會影響全球臨床實驗設計和場地選擇的決策。申辦方必須在更廣泛的病患可及性和監管多樣性所帶來的好處與臨床實驗物流日益增加的複雜性和成本之間取得平衡。總而言之，2025年的關稅強化了全行業透過地理多元化、供應商冗餘以及更緊密的商業策略和供應鏈計劃整合來增強韌性的趨勢。

揭示載體選擇、治療方式、目標基因組、遞送方式、患者人口統計、治療重點和最終用戶角色如何影響策略發展選擇

細分領域的動態揭示了不同的開發途徑和營運要求，這些對臨床策略和商業化準備有重大影響。同時，包括腺結合病毒載體、腺病毒載體、單純皰疹病毒載體和逆轉錄病毒載體在內的病毒平台因其遞送效率和組織趨向性而持續受到臨床關注。這些固有的差異影響效力測試的開發、批次放行標準和低溫運輸物流的優先順序。

治療方法帶來了監管和倫理方面的複雜性。同時，體細胞療法（包括增強基因功能和抑制有害表達的方法）是近期臨床應用的主要焦點。選擇DNA或RNA修飾作為目標基因組，進一步影響治療的持久性、脫靶風險和分析需求。 DNA編輯方法需要更全面的基因組表徵，而RNA標靶策略則需要精確、瞬時的表達控制。

遞送模式是另一個關鍵的細分軸心，體外方法需要整合細胞工程和製造能力，體內遞送強調載體生物分佈、免疫抗原性緩解和全身給藥策略。肌肉注射、眼內注射和靜脈注射等給藥途徑決定了臨床試驗設計、安全監測和治療中心的程序基礎設施。成人和兒童族群之間的患者類型分層決定了不同的終點、倫理考量和長期追蹤的承諾。心血管應用，如冠狀動脈疾病和心臟衰竭，需要與感染疾病目標（如B型肝炎和愛滋病毒）不同的終點和遞送範例。單皮病，包括囊腫纖維化、血友病和鐮狀細胞性貧血，有獨特的耐久性和校正基準。腫瘤學目標分為骨髓惡性腫瘤和固態腫瘤，需要不同的製造規模和組合策略。最終用戶動態包括委外研發機構、醫院/診所、製藥公司、生物技術公司和研究機構，每個組織的能力和採購模式各不相同，這些都會影響採用率和臨床準備度。將這些細分洞察整合到專案規劃中，可以實現有針對性的投資和風險調整後的時間表，使技術選擇與臨床和商業性需求保持一致。

解釋美洲、歐洲、中東和非洲以及亞太地區的監管、臨床和製造環境將如何影響戰略進入和營運決策

區域動態對監管方法、臨床試驗生態系統、製造投資和夥伴關係模式有重大影響。在美洲，強大的創新生態系統和活躍的資本市場支持快速的臨床應用和多個商業化上市，但該地區也面臨著集中的製造需求，促使其在產能擴張和供應鏈韌性方面進行策略性投資。該地區的臨床網路和付款人參與在證據生成和報銷實驗中發揮越來越重要的作用，塑造了新療法的商業化策略。

歐洲、中東和非洲地區法律規範和醫療保健體系結構複雜多樣，需要製定細緻入微的打入市場策略。歐洲集中的國家級監管路徑促進了協調一致的科學討論，但定價和准入方式必須因國家和地區而異。在中東和非洲市場，人們對產能建設、區域製造夥伴關係和臨床試驗參與的興趣日益濃厚，這為患者提供了替代的准入途徑，但基礎設施和報銷環境各不相同。隨著申辦方尋求在准入目標和營運可行性之間取得平衡，跨區域合作和技術轉移正變得越來越普遍。

亞太地區的特點是患者群龐大、監管機構靈活，並在多個國家/地區對生物技術基礎設施進行了大規模投資。多個市場正在積極制定獎勵，以吸引臨床試驗和生產計劃，而當地的生物製藥生態系統也正在建立日益複雜的夥伴關係關係。不同地區的監管預期和報銷準備情況各不相同，這要求相關人員採取分段式進入計劃，並投資於本地證據生成和相關人員參與，以實現治療效益。

重點介紹策略夥伴關係、製造專業化和產能投資如何重新定義主要企業的競爭定位和發展路徑

基因治療生態系統中的企業行為表明，它們重視策略聯盟、可行的垂直整合以及在載體製造和分析開發等領域的有針對性的專業化。生物技術開發商擴大與合約開發和製造組織建立長期合作夥伴關係，以確保產能，並共同投資於製程改進，從而降低單位成本並提高產品一致性。同時，大型製藥公司正在收購或授權平台技術，以擴展其治療產品線，並將某些與臨床開發和商業分銷相關的能力引入公司內部。

對內部分析能力和品質系統的投資已成為競爭優勢，使企業能夠加快可比性檢驗，並支持監管機構加快監管路徑。模組化製造解決方案和一次性技術也呈現出顯著趨勢，這些技術可部署於多個資產，以提高靈活性。策略性採購和供應商多元化已成為普遍現象，尤其是在稀有原料和專用耗材方面。企業認知到人力資本對於持續創新和卓越營運至關重要，因此優先發展載體生物學、製程開發和監管科學等先進技術領域的人才。

從企業發展角度來看，許可結構正在演變，涵蓋里程碑和與結果掛鉤的經濟因素，這反映了付款人日益重要的作用以及獎勵相關人員激勵措施的必要性。這些發展凸顯了自適應商業策略的重要性，該策略應在專案交付早期整合開發里程碑、生產準備情況和付款人參與計劃。

優先整合製造、付款人參與、產品設計、區域營運和跨職能管治，將基因治療創新轉化為永續的市場成功

產業領導者必須專注於高影響力的優先事項，並採取果斷行動，將科學潛力轉化為持續的商業性成功。首先，無論是透過策略夥伴關係或選擇性內部製造，投資於可擴展且靈活的製造能力，都可以降低專案風險，並使產品上市時間表更加可預測。此類投資應強調分析的嚴謹性、流程控制和供應鏈的多樣性，以防止單點故障並促進監管互動。

其次，早期且持續的支付方參與對於制定臨床試驗終點、真實世界證據計劃以及能夠反映臨床價值和機構可負擔性的報銷方案至關重要。設計整合臨床結果和衛生經濟指標的證據產生策略可以改善藥物的可近性，並減少上市後摩擦。第三，優先考慮平衡生物效價和可生產性的技術和方案設計。這包括選擇與現有生產能力和臨床基地準備情況相符的載體、有效載荷形式和遞送途徑。

第四，採取區域營運策略，最佳化生產、臨床試驗和商業化活動的佈局，最大限度地提高患者可及性，同時最大限度地降低關稅風險和物流複雜性。最後，實施跨職能管治結構，協調研發、監管、生產和商業團隊從專案啟動到上市的各項工作，確保決策的一致性，加速價值實現。透過落實這些優先事項，產業領導者可以縮短產品到達患者手中的時間，並提高其基因治療產品組合的整體永續性。

描述我們透明的三角調查方法，該方法結合專家訪談、科學文獻、監管指導和供應鏈分析來產生可行的見解。

本執行摘要所依據的調查方法，結合了對公開科學文獻、監管指南和行業披露資訊的結構化綜合，以及對研發、生產、監管和商業戰略領域專家的訪談，並得出了定性見解。主要資訊包括與開發人員、第三方製造商、臨床研究人員和付款人顧問的對話，這些對話揭示了公開聲明中並不常見的實際限制和策略應對措施。二次研究著重於同儕審查研究、監管溝通和技術白皮書，以支持機制和技術主張。

本研究運用資料三角測量法來協調不同的觀點並檢驗主題結論，並強調可重複性和方法透明度。在討論貿易政策影響或區域動態時，三角測量法也納入了公共聲明和對產業供應鏈的評論。調查方法認知到快速發展的科學數據固有的局限性以及許多商業性安排的專有性。因此，我們將質性研究結果與技術文獻結合，以建構穩健的、基於背景的洞察，而非進行量化預測。

在專家諮詢中，我們秉持研究誠信和保密的道德標準，並透過揭露和分發資訊來源來管理潛在的利益衝突。研究設計強調為決策者提供切實可行的見解和策略相關性，幫助他們在基因治療開發和商業化方面考慮投資、合作和營運承諾。

摘要科學進步、營運準備以及付款人和監管期望將如何融合，以確定哪些基因治療計畫將實現持續的臨床和商業性影響

基因治療正處於科學成熟度與商業性複雜性交彙的曲折點。載體工程、基因組修飾技術和臨床經驗的進步正在拓展治療的可能性，但其成功越來越依賴卓越的營運，包括生產、分析和供應鏈管理。監管機構和支付方正在推動研發機構將臨床設計和證據計劃與長期安全性和價值展示的要求相結合。這種融合凸顯了綜合策略規劃的重要性，該規劃應能預測生產限制、區域監管差異以及支付方談判。

採用整體方法，將技術選擇、患者群體策略、臨床實驗準備和報銷計劃並行不悖的開發組織，將更有能力將科學前景轉化為持續的臨床和商業性成果。建構富有彈性和靈活性的營運體系、投資關鍵分析能力以及在整個生態系統中建立合作夥伴關係關係，是應對技術和政策不確定性的切實可行的方法。隨著該領域的不斷發展，成功將青睞那些能夠平衡科學抱負與務實、以實施為導向的策略，並優先考慮患者可及性和長期安全監測的機構。

本摘要提煉了當前的結構促進因素和操作要求，為高管指南提供資訊，並指導將基因治療從實驗成功推進到持續臨床影響所需的優先投資。

目錄

第1章 引言

第2章分析方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • CRISPR鹼基編輯技術的進步使得遺傳疾病中的單鹼基精確校正成為可能
  • 脂質奈米顆粒遞送系統的出現提高了標靶效率和安全性
  • 透過新型衣殼工程降低免疫反應，AAV載體療法在臨床上獲得成功
  • 將人工智慧驅動的生物資訊整合到基因治療設計中，以最佳化載體特異性和效力
  • 全球主要市場體內基因編輯療法監管核准途徑的演變
  • 利用新型抗原標靶策略開發體外CAR-T基因修飾細胞治療固態腫瘤
  • 採用電穿孔和奈米顆粒複合物等非病毒遞送方法來降低製造成本
  • 個人化基因治療的成長由先進的基因組分析和患者特定的載體客製化推動
  • 生技公司與大型製藥公司建立策略聯盟，加速後期臨床管線開發

第6章：美國關稅的累積影響（2025年）

第7章：人工智慧（AI）的累積影響（2025年）

第8章 基因治療市場（依載體型）

  • 非病毒載體
    • 脂質體轉染
    • 質體DNA
  • 病毒載體
    • 腺結合病毒（AAV）載體
    • 腺病毒載體
    • 單純皰疹病毒（HSV）載體
    • 逆轉錄病毒載體

第9章 基因治療市場（依治療方法類型）

  • 生殖細胞治療
  • 體細胞療法
    • 基因增強療法
    • 基因抑制療法

第 10 章 基因治療市場（按目標基因組）

  • DNA修飾
  • RNA修飾

第 11 章 基因治療市場（依交付方式）

  • 體外
  • 體內

第12章 基因治療市場（依給藥途徑）

  • 肌肉注射
  • 眼
  • 靜脈

第13章 基因治療市場（依病患類型）

  • 成年患者
  • 兒科患者

第14章 基因治療市場（依治療領域）

  • 心血管疾病
    • 冠狀動脈疾病
    • 心臟衰竭
  • 感染疾病
    • B型肝炎
    • HIV
  • 單基因疾病
    • 囊腫纖維化
    • 血友病
    • 鐮狀細胞性貧血
  • 腫瘤疾病
    • 造血系統惡性腫瘤
    • 固態腫瘤

第15章 基因治療市場（依最終用戶）

  • CRO（委外研發機構）
  • 醫院和診所
  • 製藥和生物技術公司
  • 研究所

第16章 基因治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章 基因治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章 各國基因治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章 競爭態勢

  • 市佔率分析（2024年）
  • FPNV定位矩陣（2024年）
  • 競爭分析
    • Abeona Therapeutics Inc.
    • Adaptimmune Therapeutics PLC
    • Adverum Biotechnologies, Inc.
    • AGC Biologics
    • Alnylam Pharmaceuticals, Inc.
    • American Gene Technologies Inc.
    • Amgen Inc.
    • AnGes, Inc.
    • Astellas Pharma Inc.
    • Biogen Inc.
    • bluebird bio, Inc.
    • Cellectis SA
    • CRISPR Therapeutics AG
    • Danaher Corporation
    • Editas Medicine, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Gilead Sciences, Inc.
    • Intellia Therapeutics
    • Ionis Pharmaceuticals, Inc.
    • Johnson & Johnson
    • Merck KGaA
    • Mustang Bio, Inc.
    • Novartis AG
    • Orchard Therapeutics PLC
    • Poseida Therapeutics, Inc.
    • Sangamo Therapeutics, Inc.
    • Sarepta Therapeutics, Inc.
    • Sibiono GeneTech Co. Ltd.
    • Syncona Limited
    • ViGeneron GmbH
    • Voyager Therapeutics Inc.
Product Code: MRR-437517DB6C62

The Gene Therapy Market is projected to grow by USD 75.92 billion at a CAGR of 28.33% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.31 billion
Estimated Year [2025] USD 12.91 billion
Forecast Year [2032] USD 75.92 billion
CAGR (%) 28.33%

Contextualizing the evolution of gene therapy from experimental breakthroughs to integrated development and commercialization imperatives across stakeholders

The gene therapy field has moved from proof-of-concept demonstrations to a maturing ecosystem where clinical efficacy, regulatory clarity, and manufacturing scale converge to shape commercial pathways. Continued scientific breakthroughs in vector engineering and editing platforms, coupled with deeper understanding of long-term safety profiles, have expanded the set of treatable conditions and broadened investor and payer interest. As a result, strategic priorities now include not only accelerating clinical translation but also ensuring robust supply chains, standardized analytical methods, and sustainable manufacturing models that can support repeatable commercial launches.

Regulatory agencies globally are increasingly focused on harmonizing guidance around product characterization, potency assays, and long-term follow-up, which is influencing trial design and approval strategies. Concurrently, payers and health technology assessment bodies are testing innovative reimbursement mechanisms for one-time or durable therapies, prompting manufacturers to build more rigorous real-world evidence generation plans. This transition from single-asset breakthrough narratives to complex product life-cycle management demands integrated capabilities across R&D, regulatory strategy, manufacturing, and commercial operations.

In this context, decision makers must weigh technological choices-such as vector systems and delivery modes-against clinical objectives, patient populations, and logistical constraints. Interdisciplinary collaboration across academia, biotech, contract developers, and clinical networks is critical to shorten timelines while preserving safety and quality. The remainder of this executive summary synthesizes the structural shifts, policy impacts, segmentation-driven insights, regional dynamics, and practical recommendations to inform strategic investments and operational readiness across the gene therapy value chain.

Identifying concurrent technological, manufacturing, regulatory, and payer shifts that are redefining development priorities and commercial viability in gene therapy

The landscape for gene therapy is being reshaped by several transformative shifts that operate in parallel and reinforce one another. First, platform diversification has accelerated; vector technologies and genome modulation approaches have become more specialized, enabling therapies that are increasingly tailored to disease biology and patient subpopulations. This technical diversification has induced a reconfiguration of R&D pipelines, with early-stage programs emphasizing vector optimization, payload design, and manufacturability concurrently rather than sequentially.

Second, manufacturing and supply chain sophistication are emerging as strategic bottlenecks and differentiators. Developers are investing in modular, flexible manufacturing capacity and deeper engagements with contract development and manufacturing organizations to mitigate risks associated with vector scarcity and lot variability. This operational focus is complemented by a growing emphasis on analytical robustness and comparability studies to ensure batch consistency and regulatory acceptance.

Third, payer and health system conversations have moved from hypothetical affordability debates to concrete arrangements exploring outcomes-based contracts, annuity models, and real-world evidence commitments. These financing mechanisms are influencing pricing strategy, trial endpoint selection, and post-launch evidence programs. Lastly, regulatory maturation continues to be a major force, with agencies issuing iterative guidance and adopting expedited pathways for high-unmet-need indications, while also tightening expectations around long-term safety monitoring and product characterization. Together, these shifts demand integrated strategic planning that spans scientific, operational, and commercial disciplines.

Examining how United States tariff adjustments in 2025 amplified supply risk, reshaped sourcing strategies, and accelerated regional manufacturing investments across gene therapy

Tariff changes and trade policy shifts implemented in 2025 in the United States introduced new cost and logistical considerations for organizations operating in the gene therapy ecosystem. These policy adjustments have magnified the importance of geographically diversified supply chains and manufacturing footprints, as components, reagents, and specialized equipment traverse international borders with greater cost sensitivity. Companies are recalibrating sourcing strategies and inventory policies to absorb or pass through incremental import duties without compromising clinical timelines.

The immediate operational response has included prioritizing local content where feasible, accelerating qualification of alternative suppliers, and expanding regional manufacturing capacity to reduce cross-border exposure. For some developers, the added cost pressure has prompted renegotiation of vendor contracts and closer collaboration with contract manufacturers to identify mutual efficiencies. Over time, strategic capital allocation is shifting toward on-shore or near-shore capabilities for critical production steps, particularly vector manufacture and fill/finish operations, to insulate programs from tariff volatility.

At a program level, these trade dynamics also influence decision making around global trial design and site selection. Sponsors must balance the benefits of broader patient access and regulatory diversification against the added complexity and cost of cross-border logistics. In sum, tariff measures implemented in 2025 have reinforced a broader industry trend toward resilience through geographic diversification, supplier redundancy, and closer integration between commercial strategy and supply chain planning.

Articulating how vector selection, treatment modality, target genome, delivery mode, patient demographics, therapeutic focus, and end-user roles collectively shape strategic development choices

Segment-level dynamics reveal heterogeneous development pathways and operational requirements that materially affect clinical strategies and commercialization readiness. When analyzed by vector type, distinctions between non-viral and viral platforms are notable: non-viral approaches such as lipofection and plasmid DNA frequently offer advantages in dose control and manufacturing scalability, while viral platforms including adeno-associated virus vectors, adenovirus vectors, herpes simplex virus vectors, and retrovirus vectors continue to drive sustained clinical interest because of their transduction efficiency and tissue tropism. These intrinsic differences influence priorities in potency assay development, lot release criteria, and cold-chain logistics.

Treatment modality introduces regulatory and ethical complexity. Germline interventions remain subject to heightened ethical scrutiny and constrained pathways, whereas somatic cell therapies-comprising approaches that augment gene function and those that suppress deleterious expression-are the primary focus of near-term clinical translation. Choices between DNA modification and RNA modification as the target genome further affect therapeutic durability, off-target risk profiles, and analytical needs, with DNA editing approaches necessitating more extensive genomic characterization and RNA-targeting strategies demanding precise transient expression control.

Delivery mode is another pivotal segmentation axis, where ex vivo approaches require integrated cellular manipulation and manufacturing capabilities, while in vivo delivery places premium emphasis on vector biodistribution, immunogenicity mitigation, and systemic dosing strategies. Route of administration across intramuscular, intraocular, and intravenous pathways determines clinical trial design, safety monitoring, and procedural infrastructure at treatment centers. Patient type stratification between adult and pediatric populations drives differential endpoints, ethical considerations, and long-term follow-up commitments. Therapeutic area segmentation spanning cardiovascular, infectious, monogenic, and oncological disorders imposes diverse clinical evidence expectations; cardiovascular applications such as coronary artery disease and heart failure demand different endpoints and delivery paradigms than infectious disease targets like hepatitis B and HIV, while monogenic disorders including cystic fibrosis, hemophilia, and sickle cell anemia have unique durability and correctional benchmarks and oncology targets split between hematological malignancies and solid tumors require distinct manufacturing scales and combination strategies. End-user dynamics involve contract research organizations, hospitals and clinics, pharmaceutical and biotech companies, and research institutes, each bringing different capabilities and procurement models that affect adoption velocity and clinical readiness. Integrating these segmentation insights into program planning enables targeted investments and risk-adjusted timelines that align technological choice with clinical and commercial imperatives.

Explaining how regional regulatory, clinical, and manufacturing environments in the Americas, Europe Middle East & Africa, and Asia-Pacific inform strategic entry and operational decisions

Regional dynamics exert profound influence over regulatory approaches, clinical trial ecosystems, manufacturing investments, and partnership models. In the Americas, a robust innovation ecosystem and active capital markets have supported rapid clinical translation and multiple commercial launches, but this region also faces concentrated manufacturing demand that drives strategic investments in capacity expansion and supply chain resilience. Clinical networks and payer engagement in this region are increasingly central to evidence generation and reimbursement experimentation, shaping the commercialization playbook for novel therapies.

The Europe, Middle East & Africa region presents a mosaic of regulatory frameworks and health system structures, which requires nuanced market entry strategies. European centralized and national regulatory pathways encourage harmonized scientific discussion but necessitate tailored pricing and access approaches across jurisdictions. Middle Eastern and African markets show growing interest in capacity building, regional manufacturing partnerships, and clinical trial participation, offering alternative patient access routes but with variable infrastructure and reimbursement environments. Cross-region collaboration and technology transfer are becoming more common as sponsors seek to balance access goals with operational feasibility.

Asia-Pacific is characterized by a combination of large patient pools, emerging regulatory agility, and significant investments in biotechnology infrastructure across multiple countries. Several markets are proactively creating incentives to attract clinical trials and manufacturing projects, and local biopharma ecosystems are producing increasingly sophisticated partnerships. Differences in regulatory expectations and reimbursement readiness across the region require sponsors to adopt segmented entry plans and to invest in local evidence generation and stakeholder engagement to realize therapeutic impact.

Highlighting how strategic partnerships, manufacturing specialization, and capability investments are redefining competitive positioning and development pathways among leading companies

Company behaviors across the gene therapy ecosystem illustrate an emphasis on strategic partnering, vertical integration where feasible, and specialization that targets bottlenecks such as vector manufacture and analytical development. Biotech developers are increasingly forming long-term alliances with contract developers and manufacturing organizations to secure capacity and to co-invest in process improvements that reduce unit cost and enhance product consistency. Parallel to this, larger pharmaceutical companies are acquiring or licensing platform technologies to broaden therapeutic pipelines and to internalize specific capabilities around clinical development and commercial distribution.

Investment in in-house analytical capabilities and quality systems has become a competitive differentiator, enabling companies to accelerate comparability exercises and support accelerated regulatory pathways. There is also a notable trend toward modular manufacturing solutions and single-use technologies that can be deployed across multiple assets to improve flexibility. Strategic sourcing and supplier diversification are common, particularly for rare raw materials and specialized consumables. Companies are prioritizing talent development in highly technical areas such as vector biology, process development, and regulatory science, recognizing that human capital is critical to sustaining innovation and operational excellence.

From a corporate development perspective, licensing structures are evolving to include milestone and outcomes-linked economics, reflecting the increasing role of payers and the need to align incentives across stakeholders. These developments underscore the importance of adaptive commercial strategies that integrate development milestones, manufacturing readiness, and payer engagement plans early in program realization.

Prioritize integrated manufacturing, payer engagement, product design, regional operations, and cross-functional governance to convert gene therapy innovation into sustainable market success

Industry leaders should act decisively to translate scientific potential into durable commercial success by focusing on a handful of high-impact priorities. First, investment in scalable and flexible manufacturing capacity-whether through strategic partnerships or selective in-house build-will reduce program risk and enable more predictable launch timelines. Such investments should emphasize analytical rigor, process control, and supply chain diversity to guard against single-point failures and to facilitate regulatory interactions.

Second, early and ongoing payer engagement is essential to shape trial endpoints, real-world evidence plans, and reimbursement approaches that reflect both clinical value and system affordability. Designing evidence generation strategies that integrate clinical outcomes with health economic measures will improve access prospects and reduce post-launch friction. Third, prioritize technologies and program designs that balance biological potency with manufacturability; this includes choosing vectors, payload formats, and delivery routes that align with available production capabilities and clinical site readiness.

Fourth, adopt regionalized operational strategies that optimize the placement of manufacturing, clinical trials, and commercialization activities to minimize tariff exposure and logistics complexity while maximizing patient access. Finally, embed cross-functional governance structures that align R&D, regulatory, manufacturing, and commercial teams from program inception through launch to ensure coherent decision making and to accelerate value realization. By operationalizing these priorities, industry leaders can reduce time-to-patient and improve the overall sustainability of gene therapy portfolios.

Describing a transparent, triangulated research methodology that integrates expert interviews, scientific literature, regulatory guidance, and supply-chain analysis to generate actionable insights

The research approach underpinning this executive summary combined a structured synthesis of publicly available scientific literature, regulatory guidance, and industry disclosures with qualitative insights from interviews with subject matter experts across development, manufacturing, regulation, and commercial strategy. Primary inputs included conversations with developers, third-party manufacturers, clinical investigators, and payer advisors to surface practical constraints and strategic responses that are not always evident in formal publications. Secondary research emphasized peer-reviewed studies, regulatory agency communications, and technical white papers to corroborate mechanistic and technological assertions.

Data triangulation was applied to reconcile diverse perspectives and to validate thematic conclusions, with a focus on reproducibility and methodological transparency. Where trade policy impacts and regional dynamics were discussed, triangulation included public policy announcements and industry supply-chain commentaries. The methodology acknowledges limitations associated with rapidly evolving scientific data and the proprietary nature of many commercial arrangements; therefore, qualitative findings were blended with technical literature to build robust, contextualized insights rather than to produce quantitative projections.

Ethical standards for research integrity and confidentiality were maintained during expert consultations, and potential conflicts of interest were managed through disclosure and source diversification. The research design emphasizes actionable insight generation and strategic relevance for decision makers considering investment, partnership, or operational commitments in gene therapy development and commercialization.

Summarizing how scientific advances, operational readiness, and payer and regulatory expectations converge to determine which gene therapy programs achieve sustained clinical and commercial impact

Gene therapy is at an inflection point where scientific maturity and commercial complexity intersect. Advances in vector engineering, genome modulation technologies, and clinical experience have expanded the therapeutic horizon, but success increasingly depends on operational excellence across manufacturing, analytics, and supply chain management. Regulatory agencies and payers are refining expectations, driving developers to align clinical design and evidence plans with long-term safety and value demonstration imperatives. This confluence elevates the importance of integrated strategic planning that anticipates manufacturing constraints, regional regulatory variability, and payer negotiations.

Organizations that adopt a holistic approach-where technology selection, patient population strategy, site readiness, and reimbursement planning are developed in parallel-will be better positioned to translate scientific promise into sustained clinical and commercial outcomes. Building resilient and flexible operations, investing in critical analytical capabilities, and fostering collaborative partnerships across the ecosystem are practical levers to manage technical and policy uncertainties. As the field continues to evolve, success will favor those who balance scientific ambition with pragmatic, execution-oriented strategies that prioritize patient access and long-term safety monitoring.

This summary distills current structural drivers and operational imperatives intended to inform executive decision making and to guide prioritized investments necessary for advancing gene therapies from experimental success to durable clinical impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in CRISPR base editing enabling precise single-base corrections in inherited disorders
  • 5.2. Emergence of lipid nanoparticle delivery systems improving gene therapy targeting efficiency and safety
  • 5.3. Clinical success of AAV vector therapies reducing immune response through novel capsid engineering
  • 5.4. Integration of AI-driven bioinformatics in gene therapy design to optimize vector specificity and potency
  • 5.5. Regulatory approval pathways evolving for in vivo gene editing therapies across major global markets
  • 5.6. Expansion of ex vivo CAR T gene-modified cell therapies into solid tumors with novel target antigen strategies
  • 5.7. Adoption of non-viral delivery methods such as electroporation and nanoparticle conjugates to reduce manufacturing costs
  • 5.8. Growth of personalized gene therapies driven by advanced genomic profiling and patient-specific vector customization
  • 5.9. Strategic partnerships between biotech and big pharma accelerating late-stage gene therapy clinical pipelines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Therapy Market, by Vector Type

  • 8.1. Non-Viral Vectors
    • 8.1.1. Lipofection
    • 8.1.2. Plasmid DNA
  • 8.2. Viral Vectors
    • 8.2.1. Adeno-Associated Virus (AAV) Vectors
    • 8.2.2. Adenovirus Vectors
    • 8.2.3. Herpes Simplex Virus (HSV) Vectors
    • 8.2.4. Retrovirus Vectors

9. Gene Therapy Market, by Treatment Modality

  • 9.1. Germline Therapy
  • 9.2. Somatic Cell Therapy
    • 9.2.1. Gene Augmentation Therapy
    • 9.2.2. Gene Suppression Therapy

10. Gene Therapy Market, by Target Genome

  • 10.1. DNA Modification
  • 10.2. RNA Modification

11. Gene Therapy Market, by Delivery Mode

  • 11.1. Ex Vivo
  • 11.2. In Vivo

12. Gene Therapy Market, by Route of Administration

  • 12.1. Intramuscular
  • 12.2. Intraocular
  • 12.3. Intravenous

13. Gene Therapy Market, by Patient Type

  • 13.1. Adult Patients
  • 13.2. Pediatric Patients

14. Gene Therapy Market, by Therapeutic Area

  • 14.1. Cardiovascular Diseases
    • 14.1.1. Coronary Artery Disease
    • 14.1.2. Heart Failure
  • 14.2. Infectious Diseases
    • 14.2.1. Hepatitis B
    • 14.2.2. HIV
  • 14.3. Monogenic Disorders
    • 14.3.1. Cystic Fibrosis
    • 14.3.2. Hemophilia
    • 14.3.3. Sickle Cell Anemia
  • 14.4. Oncological Disorders
    • 14.4.1. Hematological Malignancies
    • 14.4.2. Solid Tumors

15. Gene Therapy Market, by End-User

  • 15.1. Contract Research Organizations
  • 15.2. Hospitals & Clinics
  • 15.3. Pharmaceutical & Biotech Companies
  • 15.4. Research Institutes

16. Gene Therapy Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Gene Therapy Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Gene Therapy Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. Abeona Therapeutics Inc.
    • 19.3.2. Adaptimmune Therapeutics PLC
    • 19.3.3. Adverum Biotechnologies, Inc.
    • 19.3.4. AGC Biologics
    • 19.3.5. Alnylam Pharmaceuticals, Inc.
    • 19.3.6. American Gene Technologies Inc.
    • 19.3.7. Amgen Inc.
    • 19.3.8. AnGes, Inc.
    • 19.3.9. Astellas Pharma Inc.
    • 19.3.10. Biogen Inc.
    • 19.3.11. bluebird bio, Inc.
    • 19.3.12. Cellectis S.A.
    • 19.3.13. CRISPR Therapeutics AG
    • 19.3.14. Danaher Corporation
    • 19.3.15. Editas Medicine, Inc.
    • 19.3.16. F. Hoffmann-La Roche Ltd.
    • 19.3.17. Gilead Sciences, Inc.
    • 19.3.18. Intellia Therapeutics
    • 19.3.19. Ionis Pharmaceuticals, Inc.
    • 19.3.20. Johnson & Johnson
    • 19.3.21. Merck KGaA
    • 19.3.22. Mustang Bio, Inc.
    • 19.3.23. Novartis AG
    • 19.3.24. Orchard Therapeutics PLC
    • 19.3.25. Poseida Therapeutics, Inc.
    • 19.3.26. Sangamo Therapeutics, Inc.
    • 19.3.27. Sarepta Therapeutics, Inc.
    • 19.3.28. Sibiono GeneTech Co. Ltd.
    • 19.3.29. Syncona Limited
    • 19.3.30. ViGeneron GmbH
    • 19.3.31. Voyager Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AMERICAS GENE THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. NORTH AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. LATIN AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. EUROPE GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. MIDDLE EAST GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASEAN GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GCC GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRICS GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. G7 GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NATO GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 36. GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GENE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GENE THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GENE THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS GENE THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS GENE THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS GENE THERAPY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
  • TABLE 320. NORTH AMERICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 323. NORTH AMERICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 324. NORTH AMERICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 325. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 326. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 327. NORTH AMERICA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 328. NORTH AMERICA GENE THERAPY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 330. LATIN AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 331. LATIN AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 332. LATIN AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 333. LATIN AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 334. LATIN AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 335. LATIN AMERICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2